Kava Anxiety Depression Spectrum Study (KADSS): A mixed methods RCT using an aqueous extract of Piper methysticum

Sarris, J; Kavanagh, DJ; Adams, J; Bone, K; Byrne, G

Kava Anxiety Depression Spectrum Study (KADSS): A mixed methods RCT using an aqueous extract of Piper methysticum

Sarris, J Kavanagh, DJ Adams, J

Bone, K Byrne, G

Permalink

Publication Type:: Journal Article
Citation:: Complementary Therapies in Medicine, 2009, 17 (3), pp. 176 - 178
Issue Date:: 2009-06-01

Closed Access

	Filename	Description	Size
	2010003355OK.pdf		114.4 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Sarris, J	en_US
dc.contributor.author	Kavanagh, DJ	en_US
dc.contributor.author	Adams, J https://orcid.org/0000-0002-9901-5717	en_US
dc.contributor.author	Bone, K	en_US
dc.contributor.author	Byrne, G	en_US
dc.date.available	2009-01-06	en_US
dc.date.issued	2009-06-01	en_US
dc.identifier.citation	Complementary Therapies in Medicine, 2009, 17 (3), pp. 176 - 178	en_US
dc.identifier.issn	0965-2299	en_US
dc.identifier.uri	http://hdl.handle.net/10453/17062
dc.description.abstract	Objectives: To report on the design, significance and potential impacts of the first documented human clinical trial assessing the anxiolytic and thymoleptic efficacy of an aqueous mono-extract of Piper methysticum (kava). The significance of the qualitative element of our clinical trial is also explored. The Kava Anxiety Depression Spectrum Study (KADSS) is a 3-week placebo-controlled, double-blind, cross-over trial involving 60 adult participants (18-65) with elevated stable anxiety and varying levels of depressive symptoms. Aims: The aims of KADSS are: (1) to determine whether an aqueous standardised extract of kava is effective for the treatment of anxiety; (2) to assess the effects of kava on differing levels of depression; and (3) to explore participants' experience of taking kava via qualitative research. The study also provides preliminary assessment of the safety of an aqueous extract of kava in humans. Conclusion: If results reveal that the aqueous kava preparation exerts significant anxiolytic effects and appears safe, potentially beneficial impacts may occur. Data supporting a safe and effective kava extract may encourage a re-introduction of kava to Europe, UK and Canada. This may provide a major socioeconomic benefit to Pacific Island nations, and to sufferers of anxiety disorders. © 2009 Elsevier Ltd. All rights reserved.	en_US
dc.relation.ispartof	Complementary Therapies in Medicine	en_US
dc.relation.isbasedon	10.1016/j.ctim.2009.01.001	en_US
dc.subject.classification	Complementary & Alternative Medicine	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Kava	en_US
dc.subject.mesh	Anti-Anxiety Agents	en_US
dc.subject.mesh	Plant Extracts	en_US
dc.subject.mesh	Phytotherapy	en_US
dc.subject.mesh	Double-Blind Method	en_US
dc.subject.mesh	Depression	en_US
dc.subject.mesh	Anxiety	en_US
dc.subject.mesh	Anxiety Disorders	en_US
dc.subject.mesh	Adolescent	en_US
dc.subject.mesh	Adult	en_US
dc.subject.mesh	Aged	en_US
dc.subject.mesh	Middle Aged	en_US
dc.subject.mesh	Patient Satisfaction	en_US
dc.subject.mesh	Young Adult	en_US
dc.title	Kava Anxiety Depression Spectrum Study (KADSS): A mixed methods RCT using an aqueous extract of Piper methysticum	en_US
dc.type	Journal Article
utslib.citation.volume	3	en_US
utslib.citation.volume	17	en_US
utslib.for	1104 Complementary and Alternative Medicine	en_US
utslib.for	1701 Psychology	en_US
dc.location.activity	ISI:000266422600009	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
pubs.organisational-group	/University of Technology Sydney/Strength - CHSP - Health Services and Practice
utslib.copyright.status	closed_access
pubs.issue	3	en_US
pubs.publication-status	Published	en_US
pubs.volume	17	en_US

Abstract:

Objectives: To report on the design, significance and potential impacts of the first documented human clinical trial assessing the anxiolytic and thymoleptic efficacy of an aqueous mono-extract of Piper methysticum (kava). The significance of the qualitative element of our clinical trial is also explored. The Kava Anxiety Depression Spectrum Study (KADSS) is a 3-week placebo-controlled, double-blind, cross-over trial involving 60 adult participants (18-65) with elevated stable anxiety and varying levels of depressive symptoms. Aims: The aims of KADSS are: (1) to determine whether an aqueous standardised extract of kava is effective for the treatment of anxiety; (2) to assess the effects of kava on differing levels of depression; and (3) to explore participants' experience of taking kava via qualitative research. The study also provides preliminary assessment of the safety of an aqueous extract of kava in humans. Conclusion: If results reveal that the aqueous kava preparation exerts significant anxiolytic effects and appears safe, potentially beneficial impacts may occur. Data supporting a safe and effective kava extract may encourage a re-introduction of kava to Europe, UK and Canada. This may provide a major socioeconomic benefit to Pacific Island nations, and to sufferers of anxiety disorders. © 2009 Elsevier Ltd. All rights reserved.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/17062